Journal
Blood Advances
Publication Date
2-25-2025
Volume
9
Issue
4
First Page
696
Last Page
703
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2024013640
Rights and Permissions
Chong EA, Penuel E, Napier EB, Lundberg RK, Budde LE, Shadman M, Matasar MJ, Bartlett NL, Flinn IW, Bosch F, Fay K, Goy A, Kumar A, Nastoupil LJ, Wei MC, Wu M, Yin S, Fraietta JA, Chong ER, Schuster SJ. Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025 Feb 25;9(4):696-703. doi: 10.1182/bloodadvances.2024013640. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Chong, Elise A; Bartlett, Nancy L; and et al., "Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas." Blood Advances. 9, 4. 696 - 703. (2025).
https://digitalcommons.wustl.edu/oa_4/4901
Additional Links
Supplemental material is available for this article at publisher site.
